部分單株抗體對於發炎症狀使用的比較表
|
Drug |
Type |
Target |
Indication |
|
|
Adalimumab |
Humanised monoclonal ab |
TNF (neutralises) |
RA (moderate-severe), PA, AS, PP, CD |
|
|
Etanercept |
Fusion protein (soluble TNF receptor/Ig) |
TNF (decoy receptor) |
RA (moderate-severe), PA, AS, PP |
|
|
Infliximab |
Chimeric ab |
TNF (neutralises) |
RAa (moderate-severe), PA, AS, PP |
|
|
Rituximab |
Chimeric monoclonal ab |
CD20 (B cells: receptor antagonist) |
RAa (moderate-severe), some malignancies |
|
|
Anakinra |
Recombinant protein |
IL-1 (receptor antagonist) |
RAa (moderate-severe) |
|
|
Abatacept |
Fusion protein |
B7 (antigen presenting cells) |
RAa (moderate-severe) |
|
|
Efalizumab |
Humanised monoclonal ab |
CD11a (leukocytes: neutralises) |
PP (moderate-severe) |
|
|
Basiliximab |
Chimeric monoclonal ab |
IL-2 receptor antagonist (lymphocytes) |
Transplantation surgery |
|
|
Daclizumab |
Humanised monoclonal ab |
IL-2 receptor antagonist (lymphocytes) |
Transplantation surgery |
|
|
Natalizumab |
Humanised monoclonal ab |
VLA-4 on lymphocytes (neutralises) |
Severe multiple sclerosis |
|
aUsed in conjunction with methotrexate.
ab, antibody; AS, ankylosing spondylitis; CD, Crohn's disease; PA, psoriatic arthritis; PP, plaque psoriasis (e.g. skin); RA, rheumatoid arthritis.
留言列表
醫藥類 (14)
